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Abstract
Primary aldosteronism (PA) is the most common form of secondary hypertension that 
causes higher morbidity and mortality than equally severe essential hypertension. 
Bilateral PA should be treated medically with spironolactone or eplerenone, the min-
eralocorticoid receptor antagonists (MRA), while unilateral laparoscopic adrenalectomy 
is recommended for unilateral disease. Surgery cures hypertension in around 40% of 
patients with confirmed PA and reliably demonstrated unilateral autonomous aldoste-
rone secretion by adrenal venous sampling (AVS). Regardless of its diagnostic value, 
AVS has several drawbacks, in particular high cost and invasiveness. Furthermore, only 
a limited number of referral centers worldwide routinely carry out the procedure. On the 
other hand, a small number of studies that compared the effects of surgery and MRA on 
the incidence of cardiovascular and renal outcomes in patients with PA found no differ-
ence between the two therapeutic options. In addition, spironolactone has been recently 
found to be the most effective add-on drug for the treatment of resistant hypertension. 
Therefore, rational selection of patients with suspected PA for AVS and surgery is of 
utmost importance.
Keywords: adrenalectomy, adrenal venous sampling, hypertension, mineralocorticoid 
receptor antagonists, primary aldosteronism
1. Introduction
Primary aldosteronism (PA) is a group of disorders in which aldosterone production is inap-
propriately high for sodium status, relatively autonomous and nonsuppressible by sodium 
loading. Such inappropriate production of aldosterone causes hypertension, sodium reten-
tion, suppression of plasma renin, and increased potassium excretion [1]. Once thought to 
be rare, PA is now considered the most common form of secondary hypertension with an 
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estimated prevalence of 4.3% in primary care and of 9.5% among referred hypertensive 
patients [2]. Accumulated experimental and clinical evidence clearly shows that prolonged 
exposure to elevated aldosterone levels causes excess cardiovascular and renal damage 
which is partly independent of blood pressure (BP) levels [3]. Consequently, this endo-
crine condition is far from being benign, and patients with PA appear to have higher rates 
of cardiac arrhythmia, coronary heart disease, heart failure, stroke, proteinuria, and renal 
impairment compared to matched patients with essential hypertension (EH) [4–6]. Their 
cardiovascular mortality might be also increased [7]. Targeted treatment of PA is possible 
and is of obvious benefit to affected patients.
The Endocrine Society now explicitly recognizes PA as a major public health issue and recom-
mends extensive screening for this disorder using the plasma aldosterone/renin ratio (ARR) in 
high-risk populations, including patients with sustained BP more than 150/100 mm Hg, resis-
tant hypertension, spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma, or 
sleep apnea. Most patients with a positive ARR should undergo one or more confirmatory 
tests to definitively confirm or exclude the diagnosis. Then lateralization of the source of the 
excessive aldosterone secretion is critical to guide the management of confirmed PA because 
unilateral adrenalectomy in patients with unilateral disease results in the normalization of 
hypokalemia; hypertension is also improved or even cured. In bilateral PA medical therapy 
with spironolactone or other mineralocorticoid receptor antagonists (MRA) is the treatment 
of choice. Unilateral disease may also be treated medically if the patient declines or is not a 
candidate for surgery. The first step in subtype classification is adrenal computed tomogra-
phy (CT). Finally, all but few surgical candidates need cumbersome adrenal venous sampling 
(AVS) to reliably distinguish between unilateral and bilateral adrenal disease and to decide 
for optimal treatment [1].
These guidelines place a high value on avoiding the risk associated with missing a diagno-
sis of unilateral PA and thus the opportunity of possibly curative intervention by unilateral 
adrenalectomy and a lower value on avoiding the risks of exposing patients with bilateral 
PA (who are candidates for medical treatment) to additional diagnostic testing. As the global 
burden of PA seems to be very high and the recommended diagnostic procedures are com-
plex and costly, consistent translation of the guidelines into clinical practice might not be 
possible even in the most affluent healthcare systems. Hence, rational approach to a patient 
with suspected PA seems the only option, and it will be briefly reviewed here. Several clinical 
situations will be presented, in order to show the different ways of medical decision-making 
in using the guidelines and to help the clinicians to apply these guidelines to their patients 
with suspected or confirmed PA.
2. Patients with suspected PA
When resources are limited, the clinician might not be able to measure plasma aldosterone 
concentration (PAC) and renin to determine ARR. Such patients should be treated with an 
MRA if they have reasonable renal function because PA is very common [2]. Moreover, there 
is ample, published supportive data that spironolactone is an excellent antihypertensive agent 
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in patients with hypertension and without PA [8, 9]. Spironolactone has even been recently 
found to be the most effective add-on drug for the treatment of resistant hypertension [10]. 
Therefore, some experts propose inclusion of a low-dose MRA (spironolactone 12.5/25 mg 
daily or equivalent doses of another antagonist) as part of first-line therapy for all hyperten-
sive subjects [11].
The Endocrine Society now similarly recommends medical treatment including an MRA, if 
an ARR-positive patient is unwilling or unable to undergo further investigations [1]. Older 
patients with multiple medical comorbidities who are at high surgical risk and those with 
short life expectancy should be included in this group [12]. Pure aldosterone-secreting adre-
nocortical carcinomas are exceptionally uncommon [13]; however, some form of adrenal 
imaging might be considered for these patients, except in cases with long-standing and mild 
(e.g., normokalemic) disease.
Notably, MRA, amiloride, triamterene, and potassium-wasting diuretics should be with-
drawn for at least 4 weeks before ARR testing. A washout of all interfering antihypertensive 
medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor block-
ers, dihydropyridine calcium channel antagonists, and beta-adrenergic blockers is feasible 
in patients with mild hypertension but is potentially problematic in others and is often not 
required if the results of ARR on the above agents are clearly diagnostic. If all potentially 
problematic agents cannot be safely withdrawn, an ARR should be performed and the results 
considered in the light of the potential confounding factors [1]. In case of very low renin lev-
els, care should be taken to avoid overinflating ARR. Only a certain minimum value of renin 
can be included in the ratio. This value is often fixed at 0.2 ng/ml/h for plasma renin activity 
(PRA) and at 0.36 ng/ml for direct renin activity (DRA). Elderly patients and individuals of 
African origin usually have low renin values, and the precautions described are vital in such 
cases [14].
3. Patients with confirmed PA
Spontaneous hypokalemia, plasma renin below detection levels, and PAC > 20 ng/dL 
(>550 pmol/L) may be sufficient for the diagnosis of PA [1]. For patients without these labo-
ratory characteristics who are undergoing confirmatory testing without MRA and thiazide 
diuretics, additional extensive medication switching is not always needed, because it appears 
that more severely excessive aldosterone overproduction (e.g., post-saline infusion test (SIT) 
PAC ≥ 8.6 ng/dL (>240 pmol/L)) may not be effectively suppressed by less interfering chronic 
antihypertensive drugs. When PA is less severe, reproducibility of confirmatory tests per-
formed without recommended drug withdrawal is much less than optimal [15].
Patients with confirmed PA and excluded adrenocortical carcinoma by CT should not be 
coerced into considering AVS and surgery if they prefer not to undergo the procedures, given 
that there is reasonable evidence to suggest that lifelong treatment with MRA is a valid alter-
native to surgery. Treatment choice should, therefore, be primarily driven by the preferences 
of the well-informed patient. Candidates for surgery should be told that the presence of an 
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adrenal adenoma poses no risk in terms of cancer [12]. In patients with an onset of confirmed 
PA earlier than 20 years of age and in those who have a family history of PA or stroke at a 
young age (<40 years), genetic testing for familial hyperaldosteronism type 1 (FH-I) [gluco-
corticoid remediable aldosteronism (GRA)] is suggested. When confirmed, FH-I should be 
always treated medically [1].
3.1. Medical therapy vs. surgery
In the absence of RCTs comparing surgical and medical treatment of PA may prove difficult, 
as a recent systematic review found. The existing studies were all carried out in a limited num-
ber of centers and were usually dealing with relatively small number of patients. Their main 
aim was to compare patients with PA and those with EH, but they failed to predefine medical 
treatment for target BP and dose or type of medication. When surgery was found the superior 
approach in those studies over the medical treatment of patients, it was often with groups that 
received no MRA or low doses of it (in some cases treatment was not reported). Furthermore, 
two different forms of PA, the unilateral disease and the bilateral disease, that may not be fully 
comparable were treated as a single one in the majority of the studies, since surgical procedures 
were mostly performed on patients with the former type of PA and medical treatment was 
delivered predominantly to those with the latter form [16]. This limits the usefulness of the 
results obtained, since it must be noted that patients with bilateral PA are in general less respon-
sive to monotherapy with MRA than those with unilateral PA [17]. Comparisons between surgi-
cally and medically treated patients with PA should, therefore, be interpreted with caution [16].
The effects on improvement of BP and hypokalemia were similar in surgically and medically 
treated patients in six studies, and surgery was reported to be superior in another six studies 
[16]. Of note, in German Conn’s registry, the observed all-cause mortality following adrenalec-
tomy was reduced compared with medical treatment [7]. However, several outcome variables 
in PA with regard to end-organ damage appear to improve to a comparable level after medi-
cal and surgical treatment. A meta-analysis of long-term studies which included 355 patients 
with PA and median follow-up of 4 years showed that reduction of left ventricular mass was 
not different after adrenalectomy or medical treatment with MRA [18]. Furthermore, when 
comparing the incidence of combined cardio- and cerebrovascular events comprising myo-
cardial infarction, stroke, any type of revascularization procedure, and sustained arrhythmias 
in treated patients with PA and matched controls with EH, the benefits of PA treatment were 
similar for specific drugs and surgery [5, 19]. Spironolactone, when uptitrated as needed and 
tolerated, is as effective as surgery in correcting the relative glomerular hyperfiltration and 
microalbuminuria of patients with PA [12]. Comparable improvement in sensitivity to insulin 
and glucose metabolism in surgically and medically treated PA was also reported [20]. No 
significant difference in prevalence of depression and anxiety was found 5.4 years after initia-
tion of MRA treatment or 4.3 years after unilateral adrenalectomy in patients with PA [21]. 
Remission of bilateral PA may occur in some patients after long-term MRA treatment [22] and 
exceptionally also in unilateral disease [23].
On the other hand, patients treated medically need more antihypertensive drugs and require 
a longer follow-up and more clinical visits at specialized referral centers than those treated 
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surgically [24]. Quality of life seems to be worse in medically treated patients with PA and 
improves more slowly and to a lesser degree than with surgical treatment [25]. Side effects are 
common in patients receiving treatment with MRA, especially spironolactone, contributing to 
increased healthcare consumption and increased risk of noncompliance [16]. Consequently, 
at least in terms of ongoing antihypertensive medication requirements and quality of life, clin-
ical responses to unilateral adrenalectomy in patients with unilateral PA are superior to those 
in patients with bilateral PA treated medically. Therefore, unilateral disease in appropriately 
selected patients is generally recommended to be treated surgically [26]. Adrenalectomy for 
PA is also less expensive than long-term medical treatment for patients with PA with a life 
expectancy of more than 25 years, performing AVS in all patients and adrenalectomy in those 
displaying lateralization than not carrying out AVS and providing lifelong drug treatment for 
all patients [27].
3.2. Selection of patients for AVS and surgery
Laparoscopic adrenalectomy, using transperitoneal or retroperitoneal approaches, is the pre-
ferred therapeutic strategy for unilateral PA [28]. It has a morbidity of 5–14%, a mortality 
below 1%, and a mean hospital stay around 3 days. Adrenalectomy generally results in the 
normalization of aldosterone secretion and serum potassium (96–100%); however, patients 
should be warned that hypertension is not always cured [29]. Based on 2482 patients from 
16 studies, BP was normalized in a mean of 42% (range 20–72%) of patients [16]. Of note, older 
studies with a “cure” rate as high as 56–77% used the cure threshold of BP < 160/95 mm Hg, 
which is clearly still in the hypertensive range [1].
3.2.1. Predictors of cure or persistent hypertension
Whether hypertension can be successfully cured or whether it is likely to persist can be 
inferred from predictors that have been extensively studied. At least one multivariate analy-
sis found the following statistically significant predictors of hypertension persistence after 
adrenalectomy in patients with unilateral PA: advanced age, male gender, longer hyperten-
sion duration, higher BMI, more drug classes, higher preoperative BP, higher 24-h urinary 
aldosterone/active renin ratio, lower estimated GFR, higher serum potassium concentrations, 
or evidence of arteriolosclerosis [29]. Recently, higher renal resistive index calculated by 
Doppler ultrasonography has been also reported to predict worse postoperative BP outcome 
in PA [30]. On the other hand, a positive predictive factor for cure is histologically verified 
aldosterone-producing adenoma [16], especially if harboring somatic KCNJ5 (inwardly rec-
tifying potassium channel, subfamily J, member 5 gene) mutations [31]. Recently, a study 
based on German Conn’s registry found out that PA patients with post-SIT PAC > 10 ng/
dL (>280 pmol/L) showed a better outcome after adrenalectomy regarding blood pressure, 
potassium normalization, and reduction in the number of antihypertensive drugs. On the 
other hand, low post-SIT PAC levels of 5–10 ng/dL (140–280 pmol/L) were an indicator of less 
successful outcome, so the authors suggested that post-SIT PAC is a predictor for the remis-
sion probability of PA post adrenalectomy [32]. Interestingly, diagnosis of unilateral PA con-
firmed by AVS was never found to be a predictor of good outcome after surgery, and patients 
with a higher lateralization index on AVS do not have a better outcome [29]. Contralateral 
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suppression on AVS correlated with good BP and biochemical outcomes from surgery in 
some [33, 34], but not in all studies [35].
Few prediction models have been developed to help clinicians to objectively inform patients 
of likely clinical outcomes before surgical intervention. The aldosteronoma resolution score 
(ARS) was composed of four readily available clinical predictors (two or fewer antihyperten-
sive medications, body mass index ≤ 25 kg/m2, duration of hypertension ≤ 6 years, and female 
sex) to identify individuals at low or high likelihood of complete resolution of hypertension. 
However, even if none of these features were present in an individual patient, he still had a 
25% probability of being completely cured by an adrenalectomy in the validation cohort [36]. 
A better option to predict BP cure after adrenalectomy might present a novel nomogram that 
has been recently developed in Japan. The included factors are the duration of hypertension, 
number of antihypertensive drug classes used, and age and sex for an individual patient 
[37]. When selecting patients for surgery, one should not attach excessive importance to these 
hypertension cure predictors. Namely, several of the studies conducted could not ascertain 
the link between these predictors and the eventual cure of the hypertension. In addition, some 
studies suffered from small sample sizes used in their multivariate analysis approach [29]. 
Factors predictive of the persistence of hypertension after adrenalectomy should not, there-
fore, be used as exclusive arguments for or against surgery in individual cases.
The most common reasons for persistently increased BP after adrenalectomy are coexistent 
EH and older age and/or longer duration of hypertension [1]. A significant number of patients 
who are not cured by adrenalectomy for PA will still benefit from surgery. Even if hyperten-
sion persists, the patient will experience a significant decrease in BP and/or treatment require-
ments. Adrenalectomy usually produces a large decrease in systolic BP (typically −25 to 
−40 mm Hg) and in the number of antihypertensive medications prescribed (typically −1 to −2 
drug classes). Additionally, the focus on hypertension cure obscures the likely cure of hypo-
kalemia and the normalization of aldosterone secretion which probably has BP-independent 
benefits [29].
3.2.2. Subtype diagnosis
Subtype diagnosis is required only if surgery is being considered. Adrenal venous sam-
pling (AVS) is currently regarded as the only reliable method to distinguish bilateral from 
unilateral PA [38]. In order to avoid an unnecessary or an inappropriate adrenalectomy, in 
principle, AVS should be performed in all patients with PA who want to pursue surgical 
cure. AVS is preceded by CT not only to exclude large masses that may represent adreno-
cortical carcinoma (Figure 1) but also to assist the interventional radiologist (and surgeon) 
where anatomically appropriate [1].
Generally, adrenal CT is not accurate in distinguishing between unilateral and bilateral dis-
ease and might have misdiagnosed the type of PA in 37.8% of patients when AVS was used 
as the criterion standard test for diagnosing laterality of aldosterone secretion (Figure 2) [38].
Morphology does not predict biochemical function, and many aldosteronomas are very small 
with up to 42% of them being <6 mm in diameter (Figure 3) [39].
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However, a recent, rigorously conducted randomized controlled trial that compared the 
outcome of CT-based management with AVS-based management for 200 patients with PA 
found no difference between the groups with regard to the intensity of antihypertensive 
drug treatment, mean blood pressure, the proportion of patients reaching target blood pres-
sure (<135/85 mm Hg), quality of life, or adverse events after 1 year. Moreover, there was 
no difference in the frequency of adrenalectomy and no statistically significant difference 
in biochemical failure in operated patients (11% in the AVS group vs. 20% in the CT group; 
p = 0.25) [40]. The outcome of this study is unexpected and challenges current guidelines. 
It is, however, important to consider that more than 70% of patients with PA present with 
normokalemia. This is a patient group not covered by the trial, and caution should be used 
in generalizing these findings [41]. In addition, when considering persistent vs. resolved PA, 
a nonsignificant trend in favor of AVS was found that might become statistically significant 
in a larger cohort [40].
Regardless of its diagnostic value, AVS has several drawbacks, in particular the lack of a 
standardized procedure, variable handling of cutoffs, high cost, and invasiveness. It has a 
Figure 1. Adrenocortical carcinoma with mineralocorticoid activity in right adrenal gland showing typical heterogeneous 
appearance and local invasion (arrow) (CT scan).
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reputation as a technically difficult procedure with the average success rate for cannulating 
the right adrenal vein of only 74% [42]. The addition of rapid intra-procedural measurement 
of adrenal vein cortisol concentrations is useful in centers with low success rates [43], and 
accuracy of catheter placement can be also improved with C-arm CT [44]. With experience 
the success rate can be improved to 90–96% [45]. The risk of adrenal hemorrhage can be 
minimized by employing a radiologist skilled in the technique, avoiding adrenal venogra-
phy and limiting the use of contrast to the smallest amounts necessary to assess the catheter 
tip position. At centers with experienced AVS radiologists, the complication rate is 2.5% or 
lower [46]. More recent studies, report, however, a substantially lower rate of complications 
Figure 2. Bilaterally enlarged adrenal glands with aldosterone-producing adenoma (20 mm) on the right and hormonally 
inactive incidentaloma (30 mm) on the left (arrows) (CT scan).
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of between 0.2 and 0.9%. Only a limited number of referral centers worldwide routinely carry 
out the procedure (Figure 4).
The Adrenal Vein Sampling International Study (AVIS) which explored AVS practice in 
20 centers from Asia, Australia, the USA, and Europe confirmed that AVS was under-
utilized with marked variation in techniques and interpretation of results and therefore 
highlighted a clear need for definitive guidelines on the use and interpretation of AVS in 
identifying unilateral aldosterone excess [47]. Importantly, different sets of criteria used 
to interpret AVS in different institutions translate into heterogeneous classifications and 
hence management decisions, for patients with PA [48]. Recently, many of these issues 
have been addressed by several opinion papers [26, 49]. An expert consensus statement 
Figure 3. Tiny aldosterone producing adenoma (6 mm) in right adrenal gland (arrow) (CT scan).
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was also reached on a number of key issues, including the preparation of the patients for 
the AVS, the procedure for its optimal performance, and the interpretation of its results for 
diagnostic purposes even in the most challenging cases [50].
Still, the most important prerequisite for overall clinical success is the selective use of AVS that 
should be based on patient preferences, patient age, clinical comorbidities, and the clinical 
probability of finding unilateral PA (Table 1) [45].
Most appropriate candidates for AVS are patients who desire surgery and are considered 
to have a high probability of unilateral PA. They have severe hypertension; higher plasma 
(>25 ng/dL (694 pmol/L)), and urinary (>30 μg/24 h (83 nmol/d)) levels of aldosterone; are 
younger (<50 years old); and have more frequent hypokalemia than those with bilateral PA 
[42]. For example, in a large prospective study of the prevalence of PA in 1125 hypertensive 
patients, spontaneous hypokalemia <3.5 mmol/L was found in only 17% of patients with bilat-
eral PA compared to about one-half of patients with unilateral disease [51]. In another smaller 
study, hypokalemia (<3.6 mmol/L) was present in 74.2% of patients with unilateral PA and in 
30.8% of patients with bilateral PA [52]. However, these factors are not absolute predictors of 
unilateral vs. bilateral adrenal disease [42].
SIT is probably the most widely used diagnostic confirmatory test for PA due to  feasibility, 
low cost, and good compliance [1]. It is a reliable alternative to the more expensive and 
complex fludrocortisone suppression test [53]. There is also some evidence to support 
its significance for distinguishing unilateral from bilateral disease. Traditionally, it was 
assumed that aldosterone secretion in patients with unilateral PA appears to be rela-
tively autonomous in response to sodium loading. On the other hand, the ability to influ-
ence aldosterone secretion was assumed to be less affected in patients with bilateral PA. 
Through a working, though abnormal feedback mechanism, they presumably responded 
Figure 4. Adrenal venous sampling (AVS) showing right (R) and left adrenal veins.
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to progressive sodium loading with decreased levels of aldosterone secretion [54]. In fact, 
when compared to patients with unilateral PA, such patients showed a greater level of 
reduction of aldosterone after SIT in a study that comprised 100 hypertensive subjects 
[53]. By contrast, in the PAPY study, no such differences of post-SIT aldosterone cutoffs 
were detected [55]. However, recent data from German Conn’s registry found out that PA 
patients with post-SIT PAC > 10 ng/dL (>280 pmol/L) had more often unilateral disease 
with larger aldosteronomas and more severe clinical manifestations, while low post-SIT 
PAC levels of 5–10 ng/dL (140–280 pmol/L) were an indicator of more frequent bilateral 
disease [32]. Similarly, PAC after shortened SIT at 2 h was significantly higher in patients 
with unilateral PA than in those with bilateral PA; however, receiver-operated character-
istic (ROC) curve analyses did not yield 100% specificity and sensitivity [56]. Apparently, 
post-SIT PAC levels provide additional useful information for the subtype classification, 
but cannot replace AVS as a reference test.
As unilateral disease is reported to be generally more sensitive to ACTH than bilateral PA, 
several groups explored significance of adrenocorticotropin stimulation test with or without 
dexamethasone suppression in determining the subtype of PA. PAC level after ACTH stimu-
lation was effective for the diagnosis of unilateral PA. The diagnostic accuracy was around 
80–90%, so this test might be used to select patients who have high probability of unilateral 
disease and definitely require AVS [57, 58].
Apparently, measurement of peripheral plasma 18-oxocortisol could contribute to the clinical 
determination between unilateral and bilateral PA. The degree of separation between the two 
subtypes in the study was considerable, with less than 40% of patients not able to be allocated 
to one or the other [59]. However, until these data are reproduced elsewhere, this surrogate 
may guide the clinician in selecting patients for AVS but should not be used to direct surgical 
management [1].
 
No AVS → adrenalectomy AVS → adrenalectomy when proven 
unilateral PA
No AVS → medical treatment
Adrenal tumor on CT with malignant 
features (e.g., possible adrenocortical 
carcinoma) [1]
Patient preference for surgical 
treatment
Patient preference for medical 
treatment
Age < 35 years with severe PA and an 
unilateral adrenal macroadenoma with 
normal contralateral gland [1, 70]
High clinical probability of unilateral 
PA (e.g., severe hypertension, 
hypokalemia, higher basal, or post-SIT 
PAC, age < 50 years) [32, 42]
Patient not suitable for surgery 
(e.g., older age and/or multiple 
comorbidities)
Positive clinical prediction score for 
unilateral PA [63, 67]
Positive clinical prediction criterion for 
bilateral PA [68]
Persistent hypertension less likely [12, 
16, 29, 36, 37]
Persistent hypertension more likely [12, 
16, 29, 36, 37]
Higher peripheral plasma 
18-oxocortisol [59]
Positive genetic testing for FH-I [1]
Note: PAC, plasma aldosterone concentration; SIT, saline infusion test; FH-I, familial hyperaldosteronism type I.
Table 1. Selective use of adrenal venous sampling (AVS) in primary aldosteronism (PA).
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Another approach might be the preselection of patients by mass spectrometry-based peripheral 
venous steroid profiling for subtyping of PA, on the basis of a report showing that correct classi-
fication of 80% of cases of unilateral vs. bilateral PA was possible by the use of a combination of 
steroids in peripheral plasma [60]. Combining imaging information with steroid profiles might 
become a future strategy to spare patients who are likely to have bilateral disease from invasive 
and costly procedures and to select patients with a high likelihood of having unilateral PA for 
direct surgery or AVS [41].
Contrary to the increased PAC sensitivity to small changes in angiotensin II concentrations, 
induced by standing upright, which was observed in patients with bilateral PA, no such 
enhancement was found in those with unilateral PA where PAC displayed diurnal variation. 
This finding served as a basis for posture simulation test [1]. Unfortunately, some aldoster-
onomas are also sensitive to angiotensin II, and some patients with bilateral PA have diurnal 
variations in aldosterone secretion, so this test is generally not useful for subtype diagnosis 
[52]. It may probably serve only an ancillary role if positive for unilateral PA in those patients 
for whom AVS was unsuccessful and CT shows a unilateral adrenal mass [1].
3.3. Alternatives to AVS
There is a persistent, ongoing search for reliable alternative methods to recognize unilateral PA 
and to identify suitable candidates for adrenalectomy without AVS but with very limited success.
3.3.1. Nuclear imaging
(6β-131 I) Iodomethyl-19-norcholesterol (NP-59) scintigraphy, performed with dexametha-
sone suppression, has the theoretical advantage of correlating function with anatomical 
abnormalities. However, the sensitivity of this test is poor in adenomas smaller than 1.5 cm 
in diameter, so it rarely plays a role in subtype evaluation [1]. (11)C-Metomidate PET-CT has 
been presented as a sensitive and specific noninvasive alternative to AVS in the management 
of PA (Figure 5) [61].
These data have not been confirmed by subsequent studies. Moreover, metomidate has low 
selectivity for aldosterone synthase (CYP11B2) over 11β-hydroxylase (CYP11B1), which 
affects its specificity for visualization of aldosterone-producing adenomas [41]. A new pre-
clinical study reported on (18)F-CDP2230, a specific aldosterone synthase tracer with a high 
selectivity for imaging zona glomerulosa that might become a promising tool for detecting 
unilateral subtypes of PA in the future [62].
3.3.2. Clinical prediction scores
Identification of unilateral PA with the help of a clinical prediction score has been proposed. 
According to the original study, the score exhibits 100% specificity for unilateral disease if 
either serum potassium concentration is lower than 3.5 mmol/L or an estimated glomeru-
lar filtration rate equals or exceeds 100 mL/min/1.73 m2, while at the same time, a unilateral 
adenoma of at least 8 mm in size has to be identifiable on a CT scan. Authors suggested that 
30% percent of the included patients would have been appropriately diagnosed as lateralized 
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based on these criteria without AVS [63]. But when later validated against international data-
bases in three separate studies, the proposed score’s specificity was seen to drop to between 80 
and 88.5%, making its reliability questionable [64–66]. A different recently developed subtype 
prediction score incorporated PAC, serum potassium, and ARR in a post-captopril challenge 
test but failed to achieve 100% specificity for unilateral PA even within the test group [67].
Therefore, most previous attempts to predict unilateral PA without AVS ultimately failed 
and could have led to wrong decisions for adrenalectomy. It might be more reasonable to 
avoid AVS only when this would not permanently influence clinical management. Patients 
with bilateral disease have the most prevalent form of PA and are usually treated medically, 
so we recently suggested that identification of patients with bilateral PA might be the right 
approach to decide for or against AVS. We conducted a retrospective diagnostic study at our 
center, in order to find variables associated with nonlateralized AVS. Combining the iden-
tified predictors, namely, serum potassium ≥ 3.5 mmol/L, post-SIT aldosterone < 18 ng/dL 
(<500 pmol/L), and either no or bilateral tumor found on CT imaging into a single criterion for 
predicting nonlateralized AVS seemed a better approach than establishing another score with 
uncertain validity. In patients with bilateral PA, the sensitivity of the combined criterion was 
determined to be modest (28.2%), but the approach yielded perfect specificity and therefore 
a positive predictive value of 100% [68]. If this rule is validated on an independent sample, 
patients with all three incorporated variables that are readily available and intuitively associ-
ated with bilateral PA by themselves [32, 42, 52] could avoid AVS and immediately start with 
medical treatment. Last but not least, it is important to emphasize that even if the proposed 
criterion proved wrong in some cases, its use would still be perfectly safe for the patient, 
because it does not attempt to predict unilateral PA as some other authors unsuccessfully did 
[63, 67]. While adrenalectomy is not without risk and its effects cannot be reversed, medical 
treatment could be stopped anytime, and the patient could proceed to AVS and surgery if 
clinically plausible. Although potentially optimal, surgery is not mandatory for PA caused by 
Figure 5. A relatively large nodule (30 mm) in left adrenal gland (CT scan) with high tracer uptake on (11)C-metomidate 
PET-CT scan identified as aldosterone-producing adenoma.
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unilateral disease, and the option of medical treatment with MRA should be discussed with 
all patients [12].
3.4. Patients with PA proceeding to surgery without AVS
It is not possible to avoid AVS in most individuals with PA who are candidates for surgery [1]. 
There are few exceptions to this rule. In the past, it was proposed by the Mayo Clinic group 
that in patients younger than 40 years with severe PA, marked spontaneous hypokalemia, and 
a clearly visible unilateral adrenal cortical macroadenoma (>1 cm and <2 cm in diameter) in 
imaging, AVS is not necessary [69]. Unfortunately, more recent data from the same authors 
showed some false positives even in this age group, and CT imaging was 100% concordant with 
AVS only in a small subgroup of patients with PA, who were younger than 35 years of age [70]. 
Similarly, in German Conn’s registry, it was not possible to rely on imaging alone after classifi-
cation of patients with an age of 40 years or younger. On the other hand, the clinical prediction 
score for unilateral PA [63] achieved a specificity of 100% when used in the same cohort [64].
4. Conclusion
A careful selection of patients for AVS is possible and should be ideally undertaken in all 
patients with PA who pursue the surgical management except in infrequent younger patients 
with Conn’s adenoma who could probably proceed directly to unilateral adrenalectomy. 
Naturally, AVS is not needed in some patients who prefer medical therapy over an adrenalec-
tomy and in those who are not suitable for surgery due to comorbidities or age. If validated on 
an independent sample, our simple clinical prediction criterion could accurately determine a 
subset of patients with bilateral PA who should avoid unnecessary AVS and immediately com-
mence with medical treatment. In addition, a careful identification of prospectively evaluated 
factors associated with long-term BP control after adrenalectomy should guide preoperative 
individual patient counseling and ultimate decision for or against AVS and surgery.
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